RT Journal Article
SR Electronic
T1 Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.19.20068015
DO 10.1101/2020.04.19.20068015
A1 Hadjadj, Jérôme
A1 Yatim, Nader
A1 Barnabei, Laura
A1 Corneau, Aurélien
A1 Boussier, Jeremy
A1 Péré, Hélène
A1 Charbit, Bruno
A1 Bondet, Vincent
A1 Chenevier-Gobeaux, Camille
A1 Breillat, Paul
A1 Carlier, Nicolas
A1 Gauzit, Rémy
A1 Morbieu, Caroline
A1 Pène, Frédéric
A1 Marin, Nathalie
A1 Roche, Nicolas
A1 Szwebel, Tali-Anne
A1 Smith, Nikaïa
A1 Merkling, Sarah H
A1 Treluyer, Jean-Marc
A1 Verer, David
A1 Mouthon, Luc
A1 Blanc, Catherine
A1 Tharaux, Pierre-Louis
A1 Rozenberg, Flore
A1 Fischer, Alain
A1 Duffy, Darragh
A1 Rieux-Laucat, Frédéric
A1 Kernéis, Solen
A1 Terrier, Benjamin
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.19.20068015.abstract
AB Background Coronavirus disease 2019 (Covid-19) is a major global threat that has already caused more than 100,000 deaths worldwide. It is characterized by distinct patterns of disease progression implying a diverse host immune response. However, the immunological features and molecular mechanisms involved in Covid-19 severity remain so far poorly known.Methods We performed an integrated immune analysis that included in-depth phenotypical profiling of immune cells, whole-blood transcriptomic and cytokine quantification on a cohort of fifty Covid19 patients with a spectrum of disease severity. All patient were tested 8 to 12 days following first symptoms and in absence of anti-inflammatory therapy.Results A unique phenotype in severe and critically ill patients was identified. It consists in a profoundly impaired interferon (IFN) type I response characterized by a low interferon production and activity, with consequent downregulation of interferon-stimulated genes. This was associated with a persistent blood virus load and an exacerbated inflammatory response that was partially driven by the transcriptional factor NFĸB. It was also characterized by increased tumor necrosis factor (TNF)-α and interleukin (IL)-6 production and signaling as well as increased innate immune chemokines.Conclusion We propose that type-I IFN deficiency in the blood is a hallmark of severe Covid-19 and could identify and define a high-risk population. Our study provides a rationale for testing IFN administration combined with adapted anti-inflammatory therapy targeting IL-6 or TNF-α in most severe patients. These data also raise concern for utilization of drugs that interfere with the IFN pathway.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Fonds IMMUNOV, for Innovation in Immunopathology. The study was also supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), by a government grant managed by the Agence National de la Recherche as part of the “Investment for the Future” program (ANR-10-IAHU-01), and by a grant from the Agence National de la Recherche (ANR-flash Covid19 “AIROCovid” to FRL). J.H. is a recipient of an Institut Imagine MD-PhD fellowship program supported by the Fondation Bettencourt Schueller. L.B. is supported by the EUR G.E.N.E. (reference #ANR-17-EURE-0013) program of the Université de Paris IdEx #ANR-18-IDEX-0001 funded by the French Government through its “Investments for the Future” program Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the microarray data (nanostring) are being processed for upload on GEO database. All the data published are available upon request to the corresponding author.